Santhera Pharmaceuticals Holding AG (XSWX:SANN) Share Price

Company Profile

Business description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
Contact
Hohenrainstrasse 24
Pratteln4133
CHE
T: +41 619068950
E: [email protected]
https://www.santhera.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
99

Recommended

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,886.60	35.90	0.41%
CAC 40	8,082.60	4.12	0.05%
DAX 40	25,435.20	60.78	0.24%
Dow JONES (US)	51,481.51	347.11	-0.67%
FTSE 100	10,704.77	19.89	0.19%
HKSE	24,523.57	118.94	-0.48%
NASDAQ	26,820.38	248.34	-0.92%
Nikkei 225	65,481.27	396.35	-0.60%
NZX 50 Index	13,683.63	147.05	-1.06%
S&P 500	7,683.69	59.72	-0.77%
S&P/ASX 200	8,709.30	29.60	0.34%
SSE Composite Index	3,830.45	6.83	0.18%